1677.1 – Pharmacy Diabetes Screening Trial

Page last updated: 20 March 2024

Application Detail

Description of Medical Service

The Pharmacy Diabetes Screening Trial compared three different pharmacy-based screening models:
1. Risk assessment using a validated tool (AUSDRISK) alone (group A)
2. AUSDRISK followed by point-of-care glycated haemoglobin (group B)
3. AUSDRISK followed by point-of-care blood glucose testing (group C)

Description of Medical Condition

Diabetes mellitus is a chronic disorder that reduces the body’s ability to produce and/or use insulin (a hormone produced by the pancreas to regulate blood sugar levels). This results in high blood sugar levels, which lead to serious complications such as stroke; diabetes-related eye disease such as diabetic retinopathy; heart disease; high blood pressure; kidney disease; vascular disease; nerve damage; and foot problems.

Reason for Application

The Sixth Community Pharmacy Agreement provided funding to support a Pharmacy Trial Program (PTP), which seeks to improve clinical outcomes for patients and/or utilise the full scope of a pharmacists role in delivering primary health care services.The outcomes of all PTP Trials will undergo an independent Health Technology Assessment (HTA) to determine the effectiveness and cost-effectiveness of the trial intervention and inform decisions about any broader rollout. A decision to fund any future programs would be a matter for Government.
Information on the PTP is available on the Department of Health’s website.

Medical Service Type

Investigative

Previous Application Number/s

1677

Associated Documentation

Consultation Survey

Consultation Survey (PDF 146 KB)
Consultation Survey (Word 71 KB)

PASC Consultation
Not applicable

MSAC Consultation
MSAC consultation input closed Friday, 16 February 2024.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Expedited – Bypassed PASC

ESC

15-16 February 2024

MSAC

-